Charles Explorer logo

Incidence of overactive bladder in patients with benign prostate hyperplasia in the Czech Republic (HYPPO- HYPerplasia of Prostate and Overactive bladder)

Publication at First Faculty of Medicine |


Overactive bladder (OAB) is a syndrome characterized by urgency, frequency, nocturia with or without urge incontinence. The aim of study was to define the incidence of OAB in patients already treated for BPH (Benign Prostate Hyperplasia).

The most frequent pharmacotherapy of BPH were alpha-blockers (73%) followed by phytopharmaca (19,9%) and finasterid (5,5%). The diagnosis of OAB was newly established in 41,2% men with BPH diagnosis.

Pharmacological treatment received 83,3% of patients with diagnosed OAB. The average duration of OAB therapy was 4,6 months.

In 26% of patients the shift to the second line of treatment (tolterodine) has been done. The average duration of the 2nd line therapy was 9,1 months (median 6,5).